Business Description
Guobang Pharma Ltd
ISIN : CNE100004NS2
Share Class Description:
SHSE:605507: Class ATotal Employee Number:
4,251Compare
Compare
Traded in other countries / regions
605507.China Index Membership
SSE Composite Index IPO Date
2021-08-02Description
Guobang Pharma Ltd is engaged in the Research, development, production and sales of products related to the pharmaceutical and animal health products fields.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.78 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 1.08 | |||||
Interest Coverage | 34.15 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 4.46 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.9 | |||||
3-Year EBITDA Growth Rate | 3.7 | |||||
3-Year EPS without NRI Growth Rate | -5 | |||||
3-Year FCF Growth Rate | 9.8 | |||||
3-Year Book Growth Rate | 6.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 15.98 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.36 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.16 | |||||
9-Day RSI | 57.44 | |||||
14-Day RSI | 55.05 | |||||
3-1 Month Momentum % | -13.38 | |||||
6-1 Month Momentum % | -24.54 | |||||
12-1 Month Momentum % | -12.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.54 | |||||
Quick Ratio | 1.86 | |||||
Cash Ratio | 1.08 | |||||
Days Inventory | 129.17 | |||||
Days Sales Outstanding | 54.21 | |||||
Days Payable | 110.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.63 | |||||
Dividend Payout Ratio | 0.43 | |||||
3-Year Dividend Growth Rate | 44.7 | |||||
Forward Dividend Yield % | 2.63 | |||||
5-Year Yield-on-Cost % | 2.77 | |||||
Shareholder Yield % | 2.52 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 25.2 | |||||
Operating Margin % | 15.41 | |||||
Net Margin % | 12.58 | |||||
EBITDA Margin % | 15.05 | |||||
FCF Margin % | 12.74 | |||||
OCF Margin % | 18.12 | |||||
ROE % | 9.16 | |||||
ROA % | 6.98 | |||||
ROIC % | 11.53 | |||||
3-Year ROIIC % | -3.49 | |||||
ROC (Joel Greenblatt) % | 15.88 | |||||
ROCE % | 10.45 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.41 | |||||
Forward PE Ratio | 14.55 | |||||
PE Ratio without NRI | 16.33 | |||||
Price-to-Owner-Earnings | 42.46 | |||||
PEG Ratio | 7.78 | |||||
PS Ratio | 2.04 | |||||
PB Ratio | 1.46 | |||||
Price-to-Tangible-Book | 1.52 | |||||
Price-to-Free-Cash-Flow | 16.18 | |||||
Price-to-Operating-Cash-Flow | 11.37 | |||||
EV-to-EBIT | 11.32 | |||||
EV-to-EBITDA | 11.32 | |||||
EV-to-Revenue | 1.7 | |||||
EV-to-FCF | 13.38 | |||||
Price-to-GF-Value | 1.02 | |||||
Price-to-Projected-FCF | 1.71 | |||||
Price-to-Graham-Number | 1.05 | |||||
| Price-to-Net-Current-Asset-Value | 3.31 | |||||
| Price-to-Net-Cash | 148.18 | |||||
Earnings Yield (Greenblatt) % | 8.83 | |||||
FCF Yield % | 6.09 | |||||
Forward Rate of Return (Yacktman) % | -2.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guobang Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 6,092.222 | ||
| EPS (TTM) (Â¥) | 0.993 | ||
| Beta | 0.9568 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.1 | ||
| Volatility % | 26.83 | ||
| 14-Day RSI | 55.05 | ||
| 14-Day ATR (Â¥) | 0.642061 | ||
| 20-Day SMA (Â¥) | 15.7655 | ||
| 12-1 Month Momentum % | -12.5 | ||
| 52-Week Range (Â¥) | 14.34 - 28.56 | ||
| Shares Outstanding (Mil) | 782.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guobang Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guobang Pharma Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.428570 Cash Dividend | 2026-05-29 | 15.56 (-1.09%) | ||
| 1.4:1 Stock Split | 2026-05-29 | 15.56 (-1.09%) | ||
| CNY 0.432736 Cash Dividend | 2025-06-13 | 15.12 (+2.37%) |
Show
Entries
Guobang Pharma Ltd Frequently Asked Questions
What is Guobang Pharma Ltd(SHSE:605507)'s stock price today?
The current price of SHSE:605507 is ¥16.30. The 52 week high of SHSE:605507 is ¥28.56 and 52 week low is ¥14.34.
When is next earnings date of Guobang Pharma Ltd(SHSE:605507)?
The next earnings date of Guobang Pharma Ltd(SHSE:605507) is .
Does Guobang Pharma Ltd(SHSE:605507) pay dividends? If so, how much?
The Dividend Yield %  of Guobang Pharma Ltd(SHSE:605507) is 2.63% (As of Today), Highest Dividend Payout Ratio of Guobang Pharma Ltd(SHSE:605507) was 0.57. The lowest was 0.12. And the median was 0.37. The  Forward Dividend Yield % of Guobang Pharma Ltd(SHSE:605507) is 2.63%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Guobang Pharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers